213 related articles for article (PubMed ID: 21649452)
1. Oral paliperidone: a review of its use in the management of schizoaffective disorder.
Yang LP
CNS Drugs; 2011 Jun; 25(6):523-38. PubMed ID: 21649452
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended release: a review of its use in the management of schizophrenia.
Chwieduk CM; Keating GM
Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone extended release: in adolescents with schizophrenia.
Perry CM
Paediatr Drugs; 2012 Dec; 14(6):417-27. PubMed ID: 23050744
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
5. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone: a review of clinical trial data and clinical implications.
Wang SM; Han C; Lee SJ; Patkar AA; Pae CU; Fleischhacker WW
Clin Drug Investig; 2012 Aug; 32(8):497-512. PubMed ID: 22747259
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
Bellantuono C; Santone G
Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
[TBL] [Abstract][Full Text] [Related]
11. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
14. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Carter NJ
Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
[TBL] [Abstract][Full Text] [Related]
15. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Owen RT
Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
Jones MP; Nicholl D; Trakas K
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.
Berwaerts J; Xu H; Nuamah I; Lim P; Hough D
J Affect Disord; 2012 Jan; 136(1-2):e51-e60. PubMed ID: 20624657
[TBL] [Abstract][Full Text] [Related]
18. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
Harrington CA; English C
Int Clin Psychopharmacol; 2010 Nov; 25(6):334-41. PubMed ID: 20706126
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
